Equine cytochrome P450 2B6–genomic identification, expression and functional characterization with ketamine.

This research article investigates the role of the equine cytochrome P450 2B6 enzyme in the metabolism of ketamine in horses. The team experimented by cloning the enzyme and assessing how it interacts with ketamine, revealing potential avenues for understanding drug interactions in veterinary medicine.

Objective and Background

• The purpose of this study was to clarify the role of the equine cytochrome P450 2B6 (CYP2B6) enzyme in metabolizing ketamine in horses. This is critical because ketamine is commonly used in veterinary medicine for anesthesia and pain management, and it is often administered alongside other drugs which can lead to possible adverse effects or reduced effectiveness because of drug-drug interactions.
• Although cytochrome P450 enzymes’ involvement in the metabolism of drugs is well-established in humans and laboratory animals, there is a knowledge gap when it comes to equine CYPs.

Methods and Observations

• The researchers cloned the coding sequence (CDS) of equine CYP2B6 from horse liver total RNA, establishing that it shares 77% sequence identity and 93.7% similarity to its human counterpart.
• A variant of equine CYP2B6 was detected in a group of 97 horses, showing an allele frequency of 82%. Two additional variants in a specific section of the gene (exon 3) were also identified in one and two horses, respectively.
• To assess the enzyme’s metabolic activity, the team introduced it into V79 Chinese hamster fibroblasts and exposed it to ketamine and norketamine. The CYP2B6 enzyme was observed to convert ketamine to norketamine and also generate other metabolites from norketamine.
• Inhibition studies were carried out to study the interaction of the enzyme with clopidogrel, a powerful inhibitor, providing values for maximum reaction speed (Vmax) and the Michaelis constant (Km).

Conclusions and Future Implications

• Through these experiments, equine CYP2B6 was confirmed to be one of the enzymes involved in the metabolism of ketamine and norketamine in horses – a conclusion in line with previous inhibition studies with horse liver microsomes.
• The significant presence of a variant allele of the CYP2B6 gene in horses suggests the potential for individual variability in ketamine metabolism, which warrants further exploration.
• This study paves the way for more research into the metabolism and drug interactions in horses, which could greatly enhance our understanding and could potentially lead to improvements in equine veterinary drug administration protocols.